Study Flaws, Data Integrity Issues Clog China Review System As Applications Soar
Total Filings Processed Up 33%
Facing a 40% increase in investigational new drug applications, regulatory reviewers in China are scrambling to turn down hundreds of filings plagued by major study design flaws, inconsistent samples and quality control failures.
